medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2015, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (3)

TRALI, a masked menace: biology and pathophysiology

Rmán TR, Fernández DND, Trujillo PHJ

Language: Spanish
References: 56
Page: 226-241
PDF size: 164.90 Kb.


ABSTRACT

Transfusion-related acute lung injury (TRALI) defined as the onset of an acute respiratory distress in a recently transfused patient, has passed from been considered a rare complication of transfusion therapy to be the leading cause of transfusion-associated death, as reported by hemovigilance systems in Europe and America. In a previous paper definition, epidemiology and some clinical aspects of TRALI are reviewed. Now we focused our efforts in reviewing the incompletely understood world of its pathogenesis. Clinically recognizable TRALI´s development depends on the interaction between risk factors from both the transfused component unit (as the kind of component and substances within it) and receiver patient´s cellular response. Heterogeneity of clinical features, transfused volumes, component type and time elapsed from the beginning of transfusion to the onset of symptoms have pushed the explanations for its genesis to evolve in an effort to include as much cases as the different hypotheses allowed. Two interesting approaches to TRALI´s pathogenesis are the “two hit” theory and the “threshold” model imposed by risk factors interactions. The large diversity of variables and causes which can influence its onset and clinical recognition continue to make it a real challenge for clinicians, mainly within transfusion medicine, where the best therapeutic approach available is prevention.


REFERENCES

  1. Popovsky MA, Abel MD, Moore SB. Transfusion related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Resp Dis. 1983;128:185-9.

  2. Keller-Stanislawski B, Reil A, Günay S, Funk MB. Frequency and severity of transfusion-related acute lung injury-German hemovigilance data (2006-2007). Vox Sang. 2010;98:70-7. doi:10.1111/j.1423-0410.2009.01232.x

  3. Funk MB, Günay S, Lohmann A, Henseler O, Heiden M, Hanschmann KMQ, et al. Benefit of transfusion-related acute lung injury risk-minimization measures-German hemovigilance data (2006-2010). Vox Sang. 2012;102:317-23. doi:10.1111/j.1423-0410.2011.01556.x

  4. Chapman CE, Stainsley D, Jones H, Love E, Massey E, Win N, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kindom, and the impact of preferential use of male donor plasma. Transfusion. 2009;49:440-52.

  5. Toy P, Gajic O, Bachetti P, Looney MR, Grooper MA, Hubmayr RD; for the TRALI Study Group. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757-67.

  6. Ozier Y, Muller JY, Mertes PM, Renaudier P, Aguilon P, Canivet N, et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion. 2011;51:2102-10. doi: 10.1111/j.1537- 2995.2011.03073.x

  7. Moore SB. Transfusion-related acute lung injury (TRALI). Clinical presentation, treatment and prognosis. Crit Care Med. 2006;34(5):114-7.

  8. Marik PE, Corwin HL. Acute lung injury following to transfusion: Expanding the definition. Crit Care Med. 2008;36:3080-4.

  9. Triulzi DJ. Transfusion-Related Acute Lung Injury: Current Concepts for the Clinician. J Anest Analg. 2009;108(3):770-6. doi: 10.1213/ane.0b013e31819029b2.

  10. Kleinman S, Caufield T, Chan P, Davenport R, McFarland J, McPhedran S, et al. Toward an understanding of transfusion-related acute lung injury: statements of a consensus panel. Transfusion. 2004;44:1774-89.

  11. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards and understanding of TRALI. Transfus Med Rev. 2005;19:2-31.

  12. Añón JM, García de Lorenzo A, Quintana M, González E, Bruscas M. Lesión pulmonar aguda producida por transfusión. Med Intens. 2010;34(2):139-149. doi: 10.1016/i.medin.2009.03.007.

  13. Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet.2013;382:984-94. DOI:10.1016/S0140-6736(12)62197-7.

  14. Román-Torres R, Fernández-Delgado N, Trujillo-Puentes H. TRALI, una amenaza enmascarada: definición, aspectos epidemiológicos y clínicos. Rev Cubana Hematol Inmunol Hemoter [revista en Internet]. 2014 [citado 2014 Sep 2];31(1): Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/177

  15. Vlaar AP, Porcelijn L, van Rooijen-Schreurs IH, Lardy NM, Kersten MJ, Juffermans NP. The divergent clinical presentations of transfusion-related acute lung injury illustrated by two case reports. Med Sci Monit. 2010;16(10):CS129-34.

  16. Benson AB, Austin GL, Berg M. Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med. 2010;36(10):1710-7.

  17. Vlaar AP, Bimekade JM, Prins D, van Stein D, Hofstra JJ, Schultz MJ, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med. 2010;38:771-8.

  18. Benjamin RJ. Tracking TRALI in target populations. Blood. 2011;117(16):4163- 4. doi:10.1182/blood-2011-03-338913.

  19. Sahz BH. Givin TRALI the one-two punch. Blood. 2012;119:1620-1. doi:10.1182/blood-2011-12-395897.

  20. Juffermans NP. Transfusion-related acute lung injury: emerging importance of host factors and implications for management. Expert Rev Hematol. 2010;3(4):459-67.

  21. Popovsky MA, Abel MD, Moore SB. Transfusion related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Resp Dis. 1983;128:185-9.

  22. Fung YL, Silliman CC. The role of neutrophils in the pathogenesis of transfusionrelated acute lung injury. Transfus Med Rev. 2009;23(4):266-83.

  23. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol. 2007;5(8):577-82.

  24. López MR, Cortina L. Daño pulmonar agudo relacionado con la transfusión. Rev Cubana Hematol Inmunol Hemoter. [revista en la Internet]. 2005 Ago [citado 2014 Sep 02]; 21(2): Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892005000200005&lng=es

  25. Lazzerini G, Del Turco S, Basta G , O'Loghlen A, Zampolli A, Caterina RD. Prominent role of NF-kappaB in the induction of endothelial activation by endogenous nitric oxide inhibition. Nitric Oxide. 2009 Nov-Dec; 21(3-4):184-91. doi:10.1016/j.niox.2009.07.007.

  26. Bozza FA, Shah AM, Weyrich AS, Zimmermann GA. Amicus or adversary: platelets in lung biology, acute injury and inflammation. Am J Respir Cell Mol Biol. 2009;40(2):123-34. doi: 10.1165/rcmb.2008-0241TR.

  27. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-5.

  28. Caudrillier A, Kessenbrock K, Gillis BM, Nguyen JX, Marques MB, Monestier M, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122(7):2661-71.

  29. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105:2266-73. doi:10.1182/blood-2004-07-2929.

  30. Storch EK, Hillyer CD, Shaz BH. Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. Blood. 2014 Sep 18;124(12):1868-72.

  31. Sahler J, Spinelli R, Phipps R, Blumberg N. CD40 ligand (CD154) involvement in platelet transfusion reactions. Transfus Clin Biol. 2012 Jun;19(3):98-103. doi: 10.1016/j.tracli.2012.02.003.

  32. Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of leukocyte antibody screening of blood donors. Vox Sang. 2008;95:313-7.

  33. Quillen K, Medrano C, Adams S, Peterson B, Hackett J, Leitman SF, et al. Screening plateletpheresis donors for HLA antibodies on two high throughput platforms and correlation with recipient outcome. Transfusion. 2011;51:504-10.

  34. Davoreen A, Curtis BR, Schulman IA, MohrbacherAF, Bux J, Kwiatkowska BJ, et al. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a(5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion. 2003;43:641-5.

  35. Müller MCA, Juffermans NP. Transfusion-related acute lung injury: a preventable syndrome? Expert Rev Hematol. 2012;5(1):97-106.

  36. Greinacher A, Wesche J, Hammer E. Characterization of the human neutrophil alloantigen-3a. Nat Med. 2010;16(1):45-8.

  37. Curtis BR, Cox NJ, Sullivan MJ. The neutrophil alloantigen HNA-3a(5b) is located on choline transporter-like protein 2 and appears to be encoded by an R>Q154 aminoacid substitution. Blood. 2010;115(10):2073-6.

  38. Bowens KL, Sullivan MJ, Curtis BR. Determination of neutrophil antigen HNA-3a y HNA-3b genotype frequencies in six racial groups by high-throughput 5´exonuclease assay. Transfusion. 2012;52(11):2368-74.

  39. Flesch BK, Wesche J, Berthold T. Expression of the CTL2 transcript variants in human peripheral blood cells and human tissues. Transfusion. 2013;53(12):3217-23.

  40. Bayat B, Tjahjono Y, Sydykov A. Anti-human neutrophil antigen-3a induced transfusión-related acute lung injury in mice by direct disturbance of lung endotelial cells. Arterioscler Thromb Vasc Biol. 2013;33(11):2538-48.

  41. Kleinman S, Triulzi DJ, Murphy EL, Carey PM, Gottschall JL, Roback JD, et al. For the National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (REDS-II). The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or negative components. Transfusion. 2011; 51:2078-91. doi:10.1111/j.1537-2995.2011.03120.x

  42. Win N, Chapman CE, Bowles KM, Green A, Bradley S, Edmondson D, et al. How much residual plasma may cause TRALI? Transf Med. 2008;18:276-80. doi:10.1111/j.1365-3148-2008.00885.x

  43. Segel GB, Halterman MW, Lichtman MA. The paradox of the neutrophil´s role in tissue injury. J Leukoc Biol. 2011;89(3):359-72.

  44. Middelburg RA, Borkent B, Jansen M, van de Watering LMG, Wiersum-Osselton JC, Schipperus MR, et al. Storage time of blood products and transfusion-related acute lung injury. Transfusion. 2012;52:658-67 doi:10.1111/j.1537-2995.2011.03352.x.

  45. Vlaar AP, Hofstra JJ, Levi M. Supernatant of aged erythrocytes causes lung inflammation and coagulopathy in a `two hit´ in vivo syngeneic transfusion model. Anesthesiology. 2010;13(1):92-103.

  46. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455-62. doi:10.1182/blood-2006-07-034736.

  47. Stronceck DF. Hot on the trail of TRALI. Blood. 2006;108(7):2136-7. doi:10.1182/blood-2006-07-034736.

  48. Silliman CC, Moore SB, Kelher MR, Khan SY, Gellar L, Elzi DJ. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion. 2011;51(12):2549-54.

  49. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils trough CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455-62.

  50. Rizvi M, Pathak D, Freedman JE, Chakrabarti S. CD40-CD40L interactions in oxidative stress, inflammantion and vascular disease. Trends Mol Med. 2008;14(12):530-8.

  51. Apelseth TO, Hervig T, Wentzel-Larsen T, Petersen K, Reikvam H, Bruseurd O. A prospective observational study of the effect of platelet transfusion on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. Eur Cytokine Netw. 2011;22(1):52-62.

  52. Wenzel F, Günter W, Baertl A, Gruber W, Sorg RV, Haas R, et al. Platelet transfusion alters CD40L blood level and release capacity in patients suffering from thrombocytopenia. Transfusion. 2011;51(12):2549-54.

  53. Bakry R, Sayed D, Galal H, Shaker S. Platelet function, activation and apoptosis during and after apheresis. Ther Apher Dial. 2010;14(5):457-64.

  54. Cognasse F, Payrat JM, Corash L, Osselaer JC, Garraud O. Platelet components associated with acute transfusion reactions: the role of platelet-derived soluble CD40 ligand. Blood. 2008;112(12):4779-80.

  55. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, et al. Plateletmediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Inmunity. 2003;19(1):9-19.

  56. Tuinman PR, Gerards MC, Jongsma G, Vlaar AP, Boon L, Juffermans NP. Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. Clin Exper Inmunol. 2011;165(2):278-84.




2020     |     www.medigraphic.com